Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyDiseaseMalignant PheochromocytomaParagangliomaSubgroupICD10C74.1C75.5MeSHParagangliomaPheochromocytomaSequenceChemotherapyChemo-substanceCyclophosphamideDacarbazineSunitinibVincristineChemo-substanceCyclophosphamideDacarbazineSunitinibVincristineChemo-substanceCyclophosphamideDacarbazineSunitinibVincristineChemo-substanceCyclophosphamideDacarbazineSunitinibVincristineNo. Substances13 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMesnaSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMesnaSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMesnaSupportive substanceBalanced Crystalloid SolutionDexamethasoneFosaprepitantGranisetronMesnaNo. Substances5Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlCardiotoxicityCystitisDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Hand-Foot SyndromeHepatotoxicityHypertensionHyponatremiaHypothyroidismIncrease AminotransferasesMucositisNeuropathyNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorAsai S Baudin EDiseaseFortgeschrittenes oder metastasiertes Phäochromozytom oder Paragangliom, ECOG 0-2Phäochromozytom, Paragangliom, fortgeschritten oder metastasiertOriginGustave Roussy, Cancer Campus, Grand Paris, FIRSTMAPP trialSt. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Kanagawa, JapanProtocols in Revision 2 protocols foundProtocols under revision.CVD - Cyclophosphamide 750 / Vincristine 2 / Dacarbazine 600, Pheochromocytoma / Paraganglioma (PID2480)Sunitinib 37.5, Pheochromocytoma / Paraganglioma (PID2485)